Cardura 4 mg 14 tablets

Trade name:

Cardura

Composition

Doxazosin mesylate 4 mg

Auxiliary components:

lactose monohydrate (milk sugar), microcrystalline cellulose, sodium carboxymethyl starch, povidone K25, magnesium stearate, sodium lauryl sulfate.

Properties

Selective competitive blocker of postsynaptic al-adrenergic receptors. It causes the expansion of peripheral vessels, which leads to a decrease in OPSS and a decrease in blood pressure. Promotes an increase in the HDL / total cholesterol ratio, a decrease in the total level of triglycerides and cholesterol.

With prolonged use, regression of left ventricular hypertrophy is observed, platelet aggregation is suppressed and the content of plasminogen activator in tissues increases. The blockade of al-adrenergic receptors located in the stroma and capsule of the prostate gland in the bladder neck leads to a decrease in resistance and pressure in the urethra, a decrease in resistance in its internal opening.

Improves urodynamics and reduces the manifestations of benign prostatic hyperplasia (BPI-I).

Indications

Benign prostatic hyperplasia (BPH); arterial hypertension (including symptomatic) as part of combination therapy.

Method of administration and dosage:

Inside. The dose and the regimen are determined individually, depending on the indications and the clinical situation.

Contraindications

Hypersensitivity to doxazosin and other quinazoline derivatives; severe hepatic impairment (in the absence of experience with this category of patients); urinary tract infections; anuria; progressive renal failure; arterial hypotension and a tendency to orthostatic disorders (including in the anamnesis); concomitant obstruction of the upper urinary tract; stones in the bladder; overflow incontinence (paradoxical ischuria); children and adolescents up to 18 years old.

With care: pulmonary edema caused by mitral stenosis or aortic stenosis; heart failure with increased cardiac output; right ventricular failure due to pulmonary embolism or exudative pericarditis; left ventricular failure with low filling pressure; disorders of cerebral circulation; age over 65 due to the risk of orthostatic symptoms (fainting, dizziness); simultaneous use with phosphodiesterase t 5 inhibitors (PDE-5) (the threat of symptomatic arterial hypotension); liver dysfunction;

pregnancy; when performing an operation for cataracts.

Side effects

From the side of the psyche: often — agitation, anxiety, insomnia; infrequently — depression.

From the nervous system: very often dizziness, headache; often — paresthesia, postural dizziness (after taking the first dose, a pronounced decrease in blood pressure is possible, which can lead to orthostatic dizziness, in severe cases, especially with a quick transition from a «lying» position to a «standing» position or to a «sitting» position to fainting ), drowsiness; infrequently hypesthesia, fainting, tremor.

Infectious and parasitic diseases: often respiratory tract infections, urinary tract infections.